Tactile Systems upgraded by BTIG Research with a new price target
$TCMD
Medical/Dental Instruments
Health Care
BTIG Research upgraded Tactile Systems from Neutral to Buy and set a new price target of $28.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/4/2025 | $28.00 | Neutral → Buy | BTIG Research |
| 10/3/2025 | $23.50 | Buy | Lake Street |
| 5/6/2025 | $14.00 | Overweight → Neutral | Piper Sandler |
| 2/19/2025 | $23.00 → $18.00 | Buy → Neutral | B. Riley Securities |
| 11/5/2024 | Outperform → Perform | Oppenheimer | |
| 11/5/2024 | Buy → Neutral | BTIG Research | |
| 9/26/2024 | $23.00 | Buy | B. Riley Securities |
MINNEAPOLIS, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the third quarter ended September 30, 2025 and announced the adoption of a second share repurchase program. Third Quarter 2025 Summary & Recent Business Highlights: Total revenue increased 17% year-over-year to $85.8 millionGross margin of 76% versus 75% in Q3 2024Net income of $8.2 million versus $5.2 million in Q3 2024Adjusted EBITDA of $14.4 million versus $10.7 million in Q3 2024Announced six-month data demonstrating sustained benefits o
MINNEAPOLIS, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced the presentation of new six-month clinical data during the late-breaking poster session at the American Congress of Rehabilitation Medicine (ACRM) 102nd Annual Fall Conference demonstrating sustained clinical benefits of Flexitouch® Plus as a first-line therapy for treating patients with head and neck cancer-related lymphedema. The six-month analysis, drawn from a large randomized controlled trial, showed improvement in lymphedema symptom burden for participants
MINNEAPOLIS, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that third quarter of fiscal year 2025 financial results will be released after the market closes on Monday, November 3, 2025. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on November 3, 2025, to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13755883. A live webcast of the call will also be provide
4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)
4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)
4 - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Issuer)
BTIG Research upgraded Tactile Systems from Neutral to Buy and set a new price target of $28.00
Lake Street initiated coverage of Tactile Systems with a rating of Buy and set a new price target of $23.50
Piper Sandler downgraded Tactile Systems from Overweight to Neutral and set a new price target of $14.00
10-Q - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Filer)
8-K - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Filer)
SCHEDULE 13G/A - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)
SC 13G/A - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)
SC 13G - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)
SC 13G - TACTILE SYSTEMS TECHNOLOGY INC (0001027838) (Subject)
MINNEAPOLIS, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the third quarter ended September 30, 2025 and announced the adoption of a second share repurchase program. Third Quarter 2025 Summary & Recent Business Highlights: Total revenue increased 17% year-over-year to $85.8 millionGross margin of 76% versus 75% in Q3 2024Net income of $8.2 million versus $5.2 million in Q3 2024Adjusted EBITDA of $14.4 million versus $10.7 million in Q3 2024Announced six-month data demonstrating sustained benefits o
MINNEAPOLIS, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that third quarter of fiscal year 2025 financial results will be released after the market closes on Monday, November 3, 2025. Management will host a conference call with a question and answer session at 5:00 p.m. Eastern Time on November 3, 2025, to discuss the results of the quarter. Those who would like to participate may dial 877-407-3088 (201-389-0927 for international callers) and provide access code 13755883. A live webcast of the call will also be provide
MINNEAPOLIS, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Summary & Recent Business Highlights: Total revenue increased 7.8% year-over-year to $78.9 millionGross margin of 75% versus 74% in Q2 2024Net income of $3.2 million versus $4.3 million in Q2 2024Adjusted EBITDA of $7.7 million versus $9.1 million in Q2 2024Announced the presentation of new data demonstrating significant benefits associated with use of Flexitouch Plus in treatin
MINNEAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced the appointment of Laura King to the Company's Board of Directors ("Board") and as a member of the Audit and Compliance & Reimbursement Committees, effective January 13, 2025. Ms. King is a seasoned healthcare executive with a proven track record of leadership and developing innovative products that enhance patient care. Her extensive experience includes a 22-year career at General Electric Company (GE), where she served as a Company Officer in her role as President & CEO of GE
PHILADELPHIA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- LifeLens Technologies, Inc. (LifeLens), a medical technology company that provides real-time physiological monitoring, today announced the appointment of three industry veterans to the following positions on its executive leadership team and Board of Directors: Daniel J. Sullivan, Chairman of the Board of LifeLens, as Chief Executive OfficerBrent A. Moen as Chief Financial OfficerRichard J. Buchholz as a member of the Board of Directors "With LifeLens, we have a significant opportunity to disrupt healthcare and make a meaningful impact on patients and healthcare professionals, and we are thrilled to have Brent and Rick join the LifeLens tea
MINNEAPOLIS, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced the appointment of Vindell Washington, M.D. to the Company's Board of Directors ("Board"), effective October 2, 2023. "We are pleased to welcome Dr. Washington to Tactile Medical, who joins our Board with over 30 years of experience in the healthcare industry," said Bill Burke, Chairman of the Board of Tactile Medical. "We will benefit from his breadth of experience in medicine, technology and policy, as well as his expertise in advising healthcare companies on their clinical s